First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer

Clinical Cancer Research

Volumn 21, Issue 8, 2015, Pages 1888-1895

  Shapiro, Geoffrey I ^a   Bell McGuinn, Katherine M ^b   Molina, Julian R ^c   Bendell, Johanna ^d   Spicer, James ^e   Kwak, Eunice L ^f   Pandya, Susan S ^g   Millham, Robert ^h   Borzillo, Gary ^h   Pierce, Kristen J ^h   Han, Lixin ^h   Houk, Brett E ^h   Gallo, Jorge D ^h   Alsina, Maria ⁱ   Braña, Irene ⁱ   Tabernero, Josep ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MAYO CLINIC   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e GUY S HOSPITAL   (United Kingdom)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h PFIZER INC   (United States)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GEDATOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; 1-(4-((4-(DIMETHYLAMINO)PIPERIDIN-1-YL)CARBONYL)PHENYL)-3-(4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL)UREA; MORPHOLINE DERIVATIVE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TRIAZINE DERIVATIVE;

ACNE; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; NAUSEA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SALIVARY GLAND CANCER; STOMATITIS; VOMITING; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; DRUG MONITORING; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; COMBINED MODALITY THERAPY; DRUG MONITORING; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORPHOLINES; NEOPLASM STAGING; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RETREATMENT; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TRIAZINES; YOUNG ADULT;

EID: 84927624149     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1306     Document Type: Article

References (26)

1. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
2. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10:143-53.
3. Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012;10:161.
4. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329-41.
5. Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Delos Santos E, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res 2011;17:3193-203.
6. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the Continual Reassessment Method for Phase 1 studies. Stat Med 1995;14:1149-61.
7. Bendell JC, Rodon J, Burris HA, De Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-90.
8. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012;18:4173-82.
9. Juric D, Rodon J, Gonzalez-Angulo AM, Burris HA, Bendell J, Berlin JD, et al. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. In: American Association for Cancer Research 103rd Annual Meeting; March 31-April 4, 2012; Chicago, IL.
10. Brana I, Lorusso P, Baselga J, Heath EI, Patnaik A, Gendreau S, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. American Society of Clinical Oncology 46th Annual Meeting; June 1-5, 2010; Chicago, IL.
11. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
12. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-10.
13. Huang A, Fritsch C, Wilson C, Reddy A, Liu M, Lehar J, et al. Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel. American Association for Cancer Research 103rd Annual Meeting; March 31-April 4, 2012; Chicago, IL.
14. Jessen K, Kessler L, Kucharski J, Guo X, Staunton J, Janes M, et al. A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. AACR-NCI-EORTC: 23rd Molecular Targets and Cancer Therapeutics; November 12-16, 2011; San Francisco, CA.
15. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic ras is a dominant predictor for resistance. Cancer Res 2009;69:143-50.
16. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30.
17. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011;10:558-65.
18. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82.
19. Rodon J, Juric D, Gonzalez-Angulo AM, Bendell J, Berlin J, Bootle D, et al. Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. AACR Annual Meeting; April 6-10, 2013; Washington DC.
20. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
21. Tabernero J, Bell-McGuinn K, Bendell J, Molina J, Kwak E, Millham R, et al. First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology. AACR-NCI-EORTC International Conference: Molecular Cancer Therapy; November 12-16, 2011; San Francisco, CA.
22. Shapiro GI, Molina J, Bendell J, Brana I, Spicer J, Kwak E, et al. First-in-human study of PF-05212384, a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics. Eur J Cancer 2010;8(Supplement):123.
23. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
24. Shapiro GI, Rodon J, Bedel C, Kwak EL, Baselga J, Braña I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014;20:233-45.
25. Haura EB, Ricard AD, Larson TG, Stella PG, Bazhenova L, Miller VA, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small-cell lung cancer. Clin Cancer Res 2010;16:2450-7.
26. Ramalingam SS, Blackhall F, Krzakwski M, Barrios CH, Park K, Bover I, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3337-44.